Procter & Gamble Health Ltd (PGHL) Q1 FY27 Results Analysis: Revenue Growth Slows to 7.4%, Margin Pressure Persists

Procter & Gamble Health Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 363.71 Cr (+7.37% YoY) and PAT growth of +45.29% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

PGHL's Q1 FY27 revenue growth slowed to 7.4% YoY, down from the mid-to-high teens pace of recent quarters, as raw material cost inflation significantly pressured margins. Operating leverage helped EBITDA grow faster than revenue, but normalized PAT rose only 9.5% after excluding a one-time exceptional gain. The high dividend payout provides shareholder return, but lack of forward guidance and decelerating growth temper the outlook.

Key Investment Insights

Key Positives

• Revenue grew 7.37% YoY to Rs.363.71 Cr.
• EBITDA (before exceptional) grew 10.25% YoY to Rs.99.60 Cr, with margin expanding 71 bps to 27.38%.
• Reported PAT grew 45.29% YoY to Rs.96.15 Cr, though inflated by exceptional gain.
• Proposed final dividend of Rs.45 per share, total FY26 dividend of Rs.205 per share.
• Company has no borrowings and negligible finance costs.

Risk Factors

• Revenue growth decelerated to 7.37% YoY from ~19% in Q4 FY26 and ~16% in FY26.
• Raw material costs surged 34.88% YoY, expanding share of revenue by 450 bps, pressuring margins.
• Employee costs rose 18.74% QoQ and other expenses rose 17.96% QoQ, indicating internal cost pressures.
• Exceptional gain of Rs.31.80 Cr distorts reported PAT; normalized PAT grew only 9.5% YoY.